Antifungal activity of Rhopalurus crassicauda venom against Candida spp.

Content Provider	Europe PMC
Author	Zottich, Umberto de Oliveira, Isadora Sousa Fereira, Isabela Gobbo Cerni, Felipe Augusto Karla de Castro Figueiredo, Bordon Arantes, Eliane Candiani Gomes, Valdirene Moreira Dias, Germana Bueno Pucca, Manuela Berto
Copyright Year	2022
Description	Highlights • Fungal infection treatment presents limited number of therapeutic drugs. • R. crassicauda venom and major toxin inhibit Candida spp. grown in vitro. • R. crassicauda venom-derived toxins may be a rich source of antifungal compounds. Fungal infections are becoming a serious problem of human diseases, being one of the most important fungal pathogens the yeast of the genus Candida. So far, fungal infection treatment faces different challenges, including the limited number of therapeutic drugs. Scorpions are known to be a valuable source of biologically active molecules, especially of peptide-derived molecules with a variety of biological effects and useful, lead compounds for drugs development. Here, we pioneer described the antifungal effect of venom, mucus, and the major toxin (Rc1) from Rhopalurus crassicauda scorpion. These results support the potential for Rc1 to be further investigated as a novel antifungal therapeutic to treat Candida infections.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8956938&blobtype=pdf
Volume Number	14
DOI	10.1016/j.toxcx.2022.100120
PubMed Central reference number	PMC8956938
PubMed reference number	35345480
Journal	Toxicon: X
e-ISSN	25901710
Language	English
Publisher	Elsevier
Publisher Date	2022-03-23
Access Restriction	Open
Rights License	This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). © 2022 The Authors
Subject Keyword	Rhopalurus crassicauda scorpion Toxin Candida albicans Candida parapsilosis Antifungal
Content Type	Text
Resource Type	Article
Subject	Toxicology